Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) is a publicly traded Healthcare sector company. As of July 17, 2026, ZNTL trades at $4.50 with a market cap of $340.27M and a P/E ratio of -2.37. ZNTL moved -1.53% today. Year to date, ZNTL is +238.52%; over the trailing twelve months it is +228.78%. Its 52-week range spans $1.01 to $6.95. Analyst consensus is buy with an average price target of $6.40. Rallies surfaces ZNTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
6 analysts cover ZNTL: 0 strong buy, 3 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $6.40.
| Metric | Value |
|---|---|
| Price | $4.50 |
| Market Cap | $340.27M |
| P/E Ratio | -2.37 |
| EPS | $-1.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.95 |
| 52-Week Low | $1.01 |
| Volume | 2.44K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-137.06M |
| Gross Margin | 0.00% |
6 analysts cover ZNTL: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.40.